# Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

> **NCT04774809** · PHASE2,PHASE3 · TERMINATED · sponsor: **Reistone Biopharma Company Limited** · enrollment: 75 (actual)

## Conditions studied

- Vitiligo

## Interventions

- **DRUG:** Low Dose SHR0302 Ointment BID
- **DRUG:** High Dose SHR0302 Ointment BID
- **OTHER:** Placebo Comparator: Vehicle

## Key facts

- **NCT ID:** NCT04774809
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-29
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** terminated by sponsor
- **Last updated:** 2022-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04774809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04774809, "Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04774809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*